Innovent Biologics Publishes Landmark Phase 3 Mazdutide Diabetes Trials in Nature
I'm PortAI, I can summarize articles.
Innovent Biologics Inc. has published results from two Phase 3 clinical studies of mazdutide, a GLP-1/GCG dual receptor agonist, in Nature. These studies, DREAMS-1 and DREAMS-2, focus on Chinese adults with type 2 diabetes. Mazdutide is approved in China for glycemic control and weight management, with ongoing studies for additional indications. The results were previously published in The New England Journal of Medicine for weight loss studies. This information was originally released by Innovent Biologics via PR Newswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments